HC Wainwright Has Positive Outlook for NTLA Q2 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at HC Wainwright raised their Q2 2026 EPS estimates for Intellia Therapeutics in a research note issued on Wednesday, May 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.74) per share for the quarter, up from their previous forecast of ($0.88). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.37) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.72) EPS, FY2026 earnings at ($3.00) EPS, Q3 2027 earnings at ($0.80) EPS and Q4 2027 earnings at ($0.76) EPS.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.11. The firm had revenue of $15.05 million during the quarter, compared to analyst estimates of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same quarter in the prior year, the business posted ($1.10) earnings per share.

NTLA has been the topic of several other reports. The Goldman Sachs Group upped their price objective on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research note on Tuesday, April 28th. Citizens Jmp upped their price objective on shares of Intellia Therapeutics from $28.00 to $30.00 and gave the stock a “market outperform” rating in a research note on Tuesday, April 28th. Sanford C. Bernstein upped their price objective on shares of Intellia Therapeutics from $13.00 to $17.00 and gave the stock a “market perform” rating in a research note on Wednesday. KeyCorp set a $25.00 price objective on shares of Intellia Therapeutics in a research note on Wednesday, January 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $20.25.

Intellia Therapeutics Trading Down 8.3%

Shares of Intellia Therapeutics stock opened at $13.09 on Friday. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -3.70 and a beta of 1.93. Intellia Therapeutics has a 1-year low of $6.83 and a 1-year high of $28.25. The firm’s 50-day moving average price is $13.64 and its two-hundred day moving average price is $11.98.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Oppenheimer & Co. Inc. boosted its stake in Intellia Therapeutics by 0.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock valued at $945,000 after acquiring an additional 808 shares during the last quarter. Comerica Bank boosted its stake in Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after acquiring an additional 901 shares during the last quarter. Federated Hermes Inc. boosted its stake in Intellia Therapeutics by 39.7% in the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock valued at $56,000 after acquiring an additional 927 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Intellia Therapeutics by 36.4% in the first quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock valued at $46,000 after acquiring an additional 948 shares during the last quarter. Finally, Wealthfront Advisers LLC boosted its stake in Intellia Therapeutics by 7.6% in the first quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock valued at $185,000 after acquiring an additional 1,018 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

Key Headlines Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $25 price target on Intellia Therapeutics, implying meaningful upside from recent trading levels. The firm also raised several forward EPS estimates, including Q2 2026, Q3 2026, Q4 2026, FY2026, and FY2027 projections.
• Positive Sentiment: HC Wainwright’s higher EPS forecasts for Q2 2026 and Q3 2026 suggest analysts see somewhat better near-term performance than before, which may help sentiment toward NTLA.
• Neutral Sentiment: Recent earnings coverage highlighted that Intellia beat first-quarter EPS and revenue estimates, but losses remain sizable and full-year expectations are still negative. This keeps the stock story focused more on pipeline potential than near-term profitability. First-quarter results and analyst forecasts
• Neutral Sentiment: Other firms, including Wells Fargo and Wedbush, reportedly remained at Hold, indicating the broader analyst view is still mixed rather than uniformly bullish. Wells Fargo hold rating
• Negative Sentiment: Some analysts, including Brookline Capital Markets, lowered earnings estimates for parts of 2026, reflecting continued concerns about Intellia’s loss trajectory and the timing of commercial progress. Brookline Capital Markets estimate changes
• Negative Sentiment: HC Wainwright also cut its price target from $30 to $25, which tempers some of the optimism despite keeping a Buy rating. HC Wainwright price target cut

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.